Anzeige
Mehr »
Montag, 09.02.2026 - Börsentäglich über 12.000 News
Goldman sieht 15.000 USD bei Kupfer - dieser Explorer ist noch völlig unbekannt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LCUL | ISIN: US14888U1016 | Ticker-Symbol: CN2
Tradegate
09.02.26 | 17:42
20,740 Euro
+0,29 % +0,060
Branche
Pharma
Aktienmarkt
S&P SmallCap 600
1-Jahres-Chart
CATALYST PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CATALYST PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
20,49020,56020:51
20,49020,56020:51

Aktuelle News zur CATALYST PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.01.CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report14
08.01.Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies8
05.01.Catalyst Pharmaceuticals, Inc.: The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)3
17.12.25Molly Harper Takes Money Off The Table, Sells $621K In Catalyst Pharmaceuticals Stock8
19.11.25Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 50017
CATALYST PHARMACEUTICALS Aktie jetzt für 0€ handeln
06.11.25Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y10
06.11.25Catalyst Pharmaceuticals, Inc. Q3 Profit Increases, Beats Estimates19
05.11.25Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update342Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance...
► Artikel lesen
05.11.25CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report1
04.11.25Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work2
22.10.25Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 20255
01.10.25CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report4
01.10.25Catalyst Pharmaceuticals Stock Rises 5% On New Share Repurchase Program6
01.10.25Catalyst Pharma Announce New Share Repurchase Program Of $200 Mln7
01.10.25Catalyst Pharmaceuticals announces $200M share repurchase program through 20265
01.10.25Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program5
09.09.25Catalyst Pharmaceuticals auf Baird-Konferenz: Strategischer Fokus auf Wachstum bei seltenen Krankheiten27
29.08.25Catalyst Pharmaceuticals President and CEO Trades $473K In Company Stock8
29.08.25Director At Catalyst Pharmaceuticals Sells $525K Of Stock6
25.08.25CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report2
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1